非布司他规范化治疗慢性肾病伴高尿酸血症的临床效果观察

Clinical Observation of Febuxostat Standardized Treatment of Chronic Kidney Disease with Hyperuricemia

目的:研究非布司他规范化治疗慢性肾病伴高尿酸血症的临床效果。方法:选取蚌埠医学院第一附属医院肾病科于2021年2月至2022年6月收治的慢性肾病伴高尿酸血症患者60例,对照组(30例)和观察组(30例),对照组采用苯溴马隆治疗,观察组采用非布司他规范化治疗。结果:观察组总有效率为93.33%,高于对照组(P<0.05)。观察组尿酸水平低于对照组,对比结果差异显著(P<0.05)。非布司他规范化治疗下慢性肾病伴高尿酸血症患者超敏C反应蛋白低于苯溴马隆治疗,而胎球蛋白A高于苯溴马隆治疗,对比结果差异显著(P<0.05)。非布司他规范化治疗下慢性肾病伴高尿酸血症患者血肌酐低于苯溴马隆治疗,而肾小球滤过率高于苯溴马隆治疗,对比结果差异显著(P<0.05)。非布司他规范化治疗下慢性肾病伴高尿酸血症患者肿瘤细胞因子α、白细胞介素6,分别低于苯溴马隆治疗,对比结果差异显著(P<0.05)。非布司他规范化治疗下慢性肾病伴高尿酸血症患者恶心、瘙痒、腹泻总发生率为6.67%,低于苯溴马隆治疗的23.33%,对比结果差异显著(P<0.05)。结论:非布司他规范化治疗慢性肾病伴高尿酸血症的临床效果显著优于苯溴马隆治疗,因此非布司他规范化治疗更具推广价值。

Objective:To study the clinical effect of febuxostadat standardized treatment of chronic kidney disease with hyperuricemia.Methods:A total of 60 patients with chronic kidney disease accompanied by hyperuricemia admitted to the Department of Nephrology,the First Affiliated Hospital of Bengbu Medical College from February 2021 to June 2022 were selected and divided into the control group(30 cases)and the observation group(30 cases).The control group was treated with benzbromarone,and the observation group was treated with febuxostatin.Results:The total effective rate of the observation group was 93.33%,which was higher than that of the control group(P<0.05).The uric acid level of the observation group was lower than that of the control group,and the difference was significant(P<0.05).The hypersensitive C-reactive protein in patients with chronic kidney disease with hyperuricemia under febuxostat standardized treatment was lower than that in benbromarone treatment,while feglobulin A was higher than that in benbromarone treatment,and the difference was significant(P<0.05).The serum creatinine of patients with hyperuricemia treated with febuxostat was lower than that treated with phenylbromarone,and the glomerular passing rate was higher than that treated with phenylbromarone,and the difference was significant(P<0.05).The tumor cytokineαand interleukin 6 of patients with chronic kidney disease with hyperuricemia under febuxostatin standardized treatment were lower than those treated with benbromarone,and the difference was significant(P<0.05).The total incidence of nausea,pruritis and diarrhea in patients with chronic kidney disease with hyperuricemia treated with febuxostatin was 6.67%,which was lower than that treated with benzbromarone(23.33%),and the difference was significant(P<0.05).Conclusion:The clinical effect of febuxostat standardized treatment of chronic kidney disease with hyperuricemia is significantly better than that of benbromarone treatment,so the standardized treatment of febuxostat is more valuable for promotion.